Dose Finding in Late-Phase Drug Development
Lei Nie(Center for Drug Evaluation and Research), Rajeshwari Sridhara(Center for Drug Evaluation and Research), R. Angelo de Claro(United States Food and Drug Administration), Kyung Y. Lee(Office of Science), Nicole Verdun(Center for Biologics Evaluation and Research)
Cited by 2
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
|The Oncologist|2018|880
FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets
|The Oncologist|2003|576
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
|New England Journal of Medicine|2021|553